Financial Performance and Losses - The company incurred net losses of $25.1 million and $75.0 million in 2025 and 2024, respectively, with an accumulated deficit of $95.6 million as of December 31, 2025[122]. - The company has not generated any meaningful revenue since inception and expects to continue incurring significant losses as it develops its main platform technology, vCLAS[122]. - The company anticipates incurring significant costs associated with launching and commercializing its products, even if it generates revenues[137]. - The company’s operating results may fluctuate significantly, making future predictions difficult and potentially affecting share price[140]. - The company may face unforeseen expenses and complications in achieving its business objectives, which could impact its financial condition[126]. - The company has incurred net operating losses (NOLs) that may be limited due to ownership changes, affecting future tax liabilities[298]. Capital and Funding Needs - The company may need to raise additional capital to fund its development and commercialization plans, which could involve issuing equity or convertible debt securities[127]. - The company has outstanding indebtedness of $20,000,000 under Convertible Securities Notes, maturing on April 30, 2028, with an interest rate of 13% per annum[293]. - A new 1% U.S. federal excise tax on stock repurchases may apply to the company, impacting financial strategies[300]. Business Model and Market Risks - The company has a limited operating history and has not yet demonstrated the ability to successfully complete clinical trials or obtain regulatory approvals[125]. - The company’s future success depends on its ability to accelerate the commercialization of its products and capitalize on market opportunities[136]. - The company’s ability to execute its business model is dependent on various factors, including market acceptance of its products[144]. - The company's future growth and profitability depend on the acceptance of its products by hospitals, physicians, patients, and payors, which is uncertain[145]. - The total addressable market for the company's products may be smaller than estimated, which could impair sales growth[153]. Competition and Market Dynamics - The company faces intense competition for skilled personnel, impacting its research and development, clinical operations, and sales efforts[168]. - Consolidation in the medical device industry may lead to increased competition and potential revenue decreases due to price concessions[170]. - The life sciences industry is highly competitive, and the company must continuously improve its products to maintain revenue and market prospects[191]. Regulatory and Compliance Challenges - The company is subject to extensive regulations from the FDA and foreign agencies, which could result in significant expenses and delays if compliance is not met[286]. - The company may face significant legal liability, including fines and penalties, if it fails to comply with evolving data privacy and security regulations[262]. - The company must ensure compliance with HIPAA regulations to protect individually identifiable health information, which involves complex analyses and safeguards[264]. - The company faces challenges in transferring personal data due to stringent localization laws in the EEA and UK, which may impact its operations[266]. - Compliance efforts with healthcare laws and regulations will involve significant costs, and violations could lead to civil, criminal, and administrative penalties[273]. Intellectual Property and Legal Risks - The company relies on patent protection and other intellectual property rights, which may not adequately protect its competitive position and could lead to increased litigation costs[211]. - The company may face substantial costs and distractions from litigation related to intellectual property rights, which could adversely affect stock prices if perceived negatively by analysts or investors[226]. - The validity and enforceability of the company's patents could be challenged, impacting competition and financial performance[229]. - The company may not be aware of all third-party intellectual property rights, leading to potential disputes and significant costs[230]. Operational and Management Challenges - The company must upgrade internal business processes to manage anticipated growth effectively, which may strain operational capabilities[162]. - The company may seek acquisitions or strategic partnerships, which could divert management's attention and increase capital requirements[165]. - The success of the company largely depends on retaining key executives and scientists, with potential difficulties arising from losing key employees[167]. Product Development and Clinical Trials - Delays in clinical trials due to various factors could significantly increase product development costs and impact market entry[182]. - The first Ventricular Tachycardia ULTA procedure using the Adagio VT Cryoablation System was announced in September 2023, marking progress in clinical trials[183]. - The company has limited data on the safety and efficacy of its products, with earlier trial results not necessarily predicting future outcomes[185]. Market and Economic Conditions - Unfavorable global economic conditions, including pandemics and political instability, could adversely affect the company's ability to raise capital and its overall financial condition[171]. - Changes in tax laws could adversely affect the company's effective tax rate and cash flows, impacting overall financial performance[304]. Stock and Market Considerations - The market price of the company's common stock may fluctuate significantly due to various factors, including operating performance and market conditions, which could lead to volatility[316]. - The company may face challenges in maintaining an active trading market for its common stock, impacting liquidity and the ability to sell shares[319].
Adagio Medical Holdings, Inc.(ADGM) - 2025 Q4 - Annual Report